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AbstrAct
Objective The clinical effectiveness of targeted 
intraoperative radiotherapy (TARGIT-IORT) has been 
confirmed in the randomised TARGIT-A (targeted 
intraoperative radiotherapy-alone) trial to be similar 
to a several weeks’ course of whole-breast external-
beam radiation therapy (EBRT) in patients with early 
breast cancer. This study aims to determine the cost-
effectiveness of TARGIT-IORT to inform policy decisions 
about its wider implementation.
setting TARGIT-A randomised clinical trial 
(ISRCTN34086741) which compared TARGIT with 
traditional EBRT and found similar breast cancer control, 
particularly when TARGIT was given simultaneously with 
lumpectomy.
Methods Cost-utility analysis using decision analytic 
modelling by a Markov model. A cost-effectiveness 
Markov model was developed using TreeAge Pro V.2015. 
The decision analytic model compared two strategies of 
radiotherapy for breast cancer in a hypothetical cohort of 
patients with early breast cancer based on the published 
health state transition probability data from the TARGIT-A 
trial. Analysis was performed for UK setting and National 
Health Service (NHS) healthcare payer’s perspective using 
NHS cost data and treatment outcomes were simulated for 
both strategies for a time horizon of 10 years. Model health 
state utilities were drawn from the published literature. 
Future costs and effects were discounted at the rate of 
3.5%. To address uncertainty, one-way and probabilistic 
sensitivity analyses were performed.
Main outcome measures Quality-adjusted life-years 
(QALYs).
results In the base case analysis, TARGIT-IORT was a 
highly cost-effective strategy yielding health gain at a 
lower cost than its comparator EBRT. Discounted TARGIT-
IORT and EBRT costs for the time horizon of 10 years 
were £12 455 and £13 280, respectively. TARGIT-IORT 
gained 0.18 incremental QALY as the discounted QALYs 
gained by TARGIT-IORT were 8.15 and by EBRT were 7.97 
showing TARGIT-IORT as a dominant strategy over EBRT. 
Model outputs were robust to one-way and probabilistic 
sensitivity analyses.
conclusions TARGIT-IORT is a dominant strategy over 
EBRT, being less costly and producing higher QALY gain.
trial registration number ISRCTN34086741; post results
IntrOductIOn
Breast cancer is the most common form 
of cancer among women in industrialised 
countries, accounting for about 30% of all 
female cancers and remains the leading 
cause of death among women aged 35–55 
years.1 2 The recommended treatment for a 
large proportion of women with early local-
ised breast cancer consists of a wide excision 
of the primary tumour. To be effective in 
controlling the disease, this preferred form 
of breast-conserving surgery needs to be 
followed by postoperative radiotherapy, tradi-
tionally delivered in the form of whole-breast 
external-beam radiation therapy (EBRT).3 
EBRT after lumpectomy for breast cancer 
reduces the risk of local recurrence in the 
conserved breast. When the reduction in local 
recurrence is more than 10% at 5 years, there 
is a demonstrable reduction in mortality at 
15 years.4 However, the disadvantage is that 
EBRT is traditionally given over 3–6 weeks 
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Research
strengths and limitations of this study
 ► This economic analysis extrapolated TARGIT-A 
(targeted intraoperative radiotherapy-alone) 
randomised trial data over a 10-year time horizon.
 ► It is the first cost-effectiveness analyis of TARGIT-
IORT using the Markov model and 5-year published 
data.
 ► Cost associated with radiation treatment toxicity and 
the higher environmental and social costs of taking 
a several weeks’ course of radiotherapy were not 
included in this study; inclusion of such costs would 
further improve the cost-effectiveness of TARGIT-
IORT.
group.bmj.com on August 17, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Vaidya A, et al. BMJ Open 2017;7:e014944. doi:10.1136/bmjopen-2016-014944
Open Access 
as a course of small daily doses of fractionated radiation. 
Such a prolonged course is inconvenient for the patients 
and also contributes substantially to a long waiting list. 
For many women, the journey to the radiotherapy centre 
is very arduous5 and many others find it prohibitive and 
choose a mastectomy instead. Furthermore, if there is a 
significant delay in treatment, the outcome from breast 
cancer can be worse.6 Over the past 20 years, diagnostic 
and therapeutic medical interventions have evolved 
into more patient-focused, less invasive techniques. The 
large international multicentre randomised controlled 
trial (RCT) of targeted intraoperative radiothera-
py-alone (TARGIT-A) that included 3451 patients from 
11 countries has confirmed that, in women with early 
breast cancer, the technique of targeted intraoperative 
radiotherapy (TARGIT-IORT) is safe and as effective.7 
TARGIT-IORT and EBRT resulted in similar local recur-
rence-free survival.8 Furthermore, recent meta-analysis of 
various partial breast irradiation versus whole-breast irra-
diation studies demonstrates a better overall survival due 
to a reduction in non-breast cancer mortality.9 10
Provisional recommendations for the use of TARGIT-
IORT with INTRABEAM in the UK National Health 
Service (NHS) were issued by the UK National Institute 
for Health and Care Excellence (NICE) on 25 July 2014.11
TARGIT-IORT during lumpectomy was included as 
a recommended option for suitable women with early 
breast cancer in the 2016 Association of Gynecological 
Oncology (AGO) guidelines; AGO is an autonomous 
community of the German Society of Gynecology and 
Obstetrics (DGGG) and the German Cancer Society.12 
The Australian Government Medical Services Advisory 
Committee recommended TARGIT-IORT for public 
funding (Medicare Benefits Schedule) after consid-
ering the available evidence in relation to safety, clinical 
effectiveness and cost-effectiveness (CE) in May 2015; it 
received budgetary approval and eligible patients from 
Australia could avail of this treatment from 1 September 
2015.13
TARGIT-IORT is being used worldwide in over 300 
centres for the treatment of breast cancer. With over 60 
centres each in the USA and Germany, centres in the 
Middle Eastern countries, Australasia, Far East, South 
America, all offering TARGIT-IORT, more than 20 000 
patients have been treated. Over 1000 patients treated in 
centres from the USA found excellent results with the use 
of TARGIT-IORT.14
Unlike regular radiotherapy, TARGIT-IORT is a single-
dose internal radiation therapy performed during surgery 
after removal of the tumour. TARGIT-IORT delivers 
radiotherapy directly into the tumour bed. It is adminis-
tered at the time of lumpectomy, immediately following 
cancer removal, during the same anaesthetic, using a 
radiation device INTRABEAM, which was developed by 
University College London clinical scientists in collabo-
ration with the industry. The radiation is switched on for 
25–30 min and is accurately targeted to the tissues that are 
at highest risk of local recurrence. The TARGIT-A trial 
showed how such a single dose of TARGIT-IORT given at 
the time of surgery could eliminate the need for whole-
breast EBRT in over 80% of suitable patients. This would 
avoid numerous hospital visits and minimise radiation 
exposure to healthy tissue and organs.
Although it is obvious that the cost of a treatment 
consisting of a single dose of radiation is likely to be less 
than a 3–6 weeks’ course of radiation, it is only a formal 
CE analysis that can objectively determine the exact 
difference in cost.
Therefore, this work aims to determine the CE of 
TARGIT-IORT in patients with early breast cancer. This 
is necessary as such health economic evaluation of the 
TARGIT-IORT using INTRABEAM could inform reim-
bursement policy decisions and its implementation in 
usual practice. We assessed the CE of TARGIT-IORT 
compared with EBRT for the treatment of early breast 
cancer in the UK.
MAterIAls And MethOds
Model approach
Modelling is a valuable tool in the systematic and trans-
parent synthesis of evidence to support policy decisions. 
With a series of numbers and mathematical and statistical 
relationships, modelling creates a representation of real-
world events.15 To assess the clinical, social and economic 
benefits of TARGIT-IORT over the current practice 
of whole-breast irradiation, we constructed a decision 
analytic model based on outcome probabilities from the 
published TARGIT-A trial data (prepathology cohort) 
and costs from the INTRABEAM manufacturer and UK 
NHS tariffs.7 Utility values for the model health states 
were drawn from the published literature.16 A CE Markov 
model was developed using TreeAge Pro V.2015 (TreeAge 
Software, Williamstown, Massachusetts, USA) to capture 
the costs and outcomes of the two breast cancer radia-
tion therapy options, namely: conventional whole-breast 
radiation as reference strategy and TARGIT-IORT using 
INTRABEAM as new innovative strategy. Model outputs 
were represented in terms of life-years, quality-adjusted 
life-years (QALYs), cost and CE ratio. The analysis was 
conducted from the NHS healthcare payer’s perspective 
and to address uncertainty, one-way and probabilistic 
sensitivity analyses were performed. A discount rate of 
3.5% was applied to the future costs and effects as per the 
NICE pharmacoeconomic guidelines.17
Model description
The decision analytic model compared two competing 
breast cancer radiation strategies in a hypothetical cohort 
of patients with early breast cancer. Treatment outcomes 
were simulated for both strategies for a time horizon of 
10 years. We used the TARGIT-A trial as an evidence to 
inform the model structure and incorporated disease 
progression as various model health states.7 Currently, 
these clinical effectiveness data published in the Lancet 
are the only level 1 randomised evidence available for the 
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Figure 1 Markov model structure. EBRT, external-beam radiation therapy; TARGIT-IORT, targeted intraoperative radiation 
therapy.
TARGIT-IORT. The TARGIT-A trial was conducted as a 
pragmatic risk-adapted design reflecting a real-world situ-
ation.7 
Our model uses five distinct health states: disease free; 
local recurrence; distant recurrence; death from breast 
cancer; and non-breast cancer death (figure 1). The 
TARGIT-A trial defines ‘local recurrence’ as recurrence 
in the conserved breast. All patients start the model in 
the disease-free state and may then either: stay in the 
disease-free state; have a distant recurrence; have a local 
recurrence; or die from non-breast-cancer(BC) causes. 
Patients moving to the distant recurrence health states 
may remain there or die of breast cancer death. Model 
cycle length was 1 year.
Model parameters
Transition probabilities
The baseline disease progression parameters used in the 
model were obtained from the TARGIT-A trial. Since 
TARGIT-A is the only available trial for TARGIT-IORT 
effectiveness, all the transition probabilities were calcu-
lated using these data. Five-year events rates published in 
the study were converted to annual rates using MS Excel 
natural logarithm (ln) function and then to annual prob-
abilities using exponential function.7
Costs
The costs included in the model are those for initial radi-
ation treatment by EBRT and TARGIT-IORT along with 
the costs of being disease free, cost of local and distant 
recurrences. The cost of TARGIT-IORT was supplied 
by the manufacturer of INTRABEAM device and was 
confirmed with experts. Cost of EBRT includes cost to 
deliver 15 fractions of radiotherapy on a megavoltage 
machine and the cost of preparation for simple radio-
therapy. NICE clinical guideline 80 recommends delivery 
of 15 fractions of radiotherapy to complete a course of 
treatment.18 As per the experts, these costs are £157 per 
fraction of radiotherapy and £737 for the preparation. 
Costs of EBRT and cost of disease-free health states were 
taken from the NHS Reference Costs 2012–2013 using a 
Health Resource Group (HRG) code. HRG coding is an 
activity-based payment system of the NHS England and 
HRG grouping consists of patient events that have been 
judged to consume a similar level of resource. Costs of 
recurrences were taken from published literature19 and 
were converted to year 2014 costs using Bank of England 
cost conversion tool.20 Total costs of recurrences included 
diagnostic and treatment costs of recurrences (local/
distant).
Utility
Utility values for various health states in the model were 
assigned from the published literature.19 Authors have 
reported that a cross-sectional study of 26 representative 
UK patients with early breast cancer was used to derive 
utilities for various health states in the model. Utilities for 
different health states were elicited using standard gamble 
method that compared the health states to perfect and 
worse health and then worse health against perfect health 
and death. The patients in the various health states in the 
model were assigned these utility weights to estimate the 
number of QALYs gained. The details of model param-
eter value point estimates, ranges and their sources are 
given in table 1.
Model assumptions
a. All patients enter the model in the disease-free state 
after initial breast cancer surgery and radiation 
therapy. In this state, patients can die of non-breast 
cancer causes.
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Figure 2 Incremental cost-effectiveness scatterplot. Each of the 1000 dots represents the result of the Monte Carlo simulation 
of cost-effectiveness of TARGIT-IORT over EBRT. So, if the dot is above the WTP threshold, it means that additional cost is 
involved in adopting TARGIT-IORT. If it is below the WPT threshold, then there is health gain at lower cost. In this plot, 97.8% 
of the dots are below the WTP threshold of zero. EBRT, external-beam radiation therapy; TARGIT-IORT, targeted intraoperative 
radiation therapy; WTP, willingness to pay.
b. It is only possible to die from breast cancer while in 
the distant recurrence state.
c. All patients from the local recurrence state are back 
to the disease-free state after treatment of local 
recurrence.
Model analysis
The model assumes that the patient is always in one of a 
finite number of states of health referred to as Markov 
states. The time horizon of the analysis is divided into 
equal increments of time, referred to as Markov cycles, 
in this case 1 year. During each cycle, the cohort of 
patients is redistributed over the Markov states, thus 
theoretically patients may make a transition from one 
state to another. Each state is assigned a utility and a 
cost. Total costs and utility for TARGIT-IORT versus 
EBRT for the model time horizon were calculated 
depending upon the distribution of the cohort over 
the Markov states and the length of time spent in each 
state. Discounted and undiscounted expected life-years 
and costs (discount rate 3.5%) for both strategies were 
calculated. Based on the discounted expected values, 
the incremental cost-effectiveness ratio (ICER) for 
TARGIT-IORT was calculated over EBRT.
Model uncertainty
Sensitivity analysis is intended to allow for the examina-
tion of the effects of uncertainties on the results of an 
economic evaluation. In any economic model, various 
inputs, including outcome probabilities and costs, are 
required. These typically come from different sources 
and may be associated with uncertainty. In sensitivity 
analysis, the values of these inputs are changed (usually 
between a reasonable maximum and minimum value), 
and the model is rerun. The extent to which the conclu-
sions that the economic evaluation lead to (eg, one 
option is more cost-effective than the other) are consis-
tent across a range of sensitivity analyses reflects the 
robustness of the findings. To address the uncertainty 
about the clinical effects of treatment, one-way sensi-
tivity analysis and probabilistic sensitivity analysis (PSA) 
were performed.
In a one-way sensitivity analysis, a single input is varied 
between a maximum and minimum value (±25%). In 
PSA, each input parameter into the model is assumed 
to arise from a probabilistic distribution of values for 
that input. For the one-way (deterministic) sensitivity 
analysis, the highest and lowest values of each input 
parameter were assumed to be 25% above and below 
the original estimate for that parameter.
For PSA, second-order Monte Carlo simulation was 
performed to test parameter uncertainty (variability 
between different samples coming from one popula-
tion). PSA allows systematic propagation of uncertainty 
in all model parameters by assigning distributions to 
parameters and using a Monte Carlo simulation tech-
nique. All model parameters derived from the literature 
or other sources were considered for accuracy, credi-
bility and plausibility at meetings of the expert panel. 
In some cases, identifying a suitable distribution for 
estimates and describing the uncertainty around these 
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Table 2 Cost-effectiveness results
Strategy Cost Incremental cost Effectiveness Incremental effect ICER
EBRT 13 280 Reference strategy 7.97 Reference strategy
TARGIT-IORT 12 455 −825 8.15 0.18 Dominant
EBRT, external-beam radiation therapy; ICER, incremental cost effectiveness ratio; TARGIT-IORT, targeted intraoperative radiation therapy.
Figure 3 Monte Carlo acceptability. These bar charts show the number of ICER simulation results as seen in figure 2, above 
and below the WTP threshold of zero. It shows that there is a 97.8% probability of TARGIT-IORT being cost effective at the WTP 
threshold of zero; the corresponding probability for EBRT being cost-effective is 2.2%. EBRT, external-beam radiation therapy; 
TARGIT-IORT, targeted intraoperative radiation therapy; WTP, willingness to pay.
values was problematic. Therefore, in such circum-
stances, uncertainty was calculated as a potential range 
of plausible values of ±25% of the estimate. It was 
assumed that the point estimate was the most likely 
‘real’ value and therefore, by using the triangular distri-
bution it was ensured that the upper and lower bounds 
of variability did not exceed clinical plausibility. This 
distribution emphasises the ‘most likely’ value over the 
minimum and maximum estimates. A triangular distri-
bution is a continuous probability distribution with a 
probability density function shaped like a triangle. 
It is defined by three values: the minimum value, the 
maximum value and the real (peak) value. The trian-
gular distribution has a definite upper and lower limit 
to avoid extreme values.
Results of 1000 Monte Carlo simulations were graph-
ically displayed in the form of CE planes showing the 
uncertainty surrounding the CE of TARGIT-IORT and its 
subsequent probability of being cost-effective at different 
values of willingness to pay (WTP) thresholds was shown 
as Monte Carlo CE acceptability chart.
results
Base case results
In the base case analysis, TARGIT-IORT was a highly 
cost-effective strategy yielding health gain at a lower cost 
than its comparator EBRT. The difference in the cost 
of delivery of TARGIT-IORT versus EBRT was £1023, 
favouring TARGIT-IORT. Discounted TARGIT-IORT and 
EBRT costs for the time horizon of 10 years were £12 455 
and £13 280, respectively. TARGIT-IORT gained 0.18 
incremental QALY as the discounted QALYs gained by 
TARGIT-IORT were 8.15 and by EBRT were 7.97. TARGIT-
IORT dominated EBRT as it provides an additional QALY 
at a lower cost than EBRT (table 2).
results of sensitivity analyses
One-way sensitivity analyses revealed that the model was 
robust to all one-way sensitivity analyses and TARGIT-
IORT remains a dominant strategy over EBRT in all 
parameter variations. Probabilistic sensitivity analyses 
were conducted to estimate the effect of overall uncer-
tainty in the economic evaluation through repeated 
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sampling of mean parameter values from a series of 
assigned distribution. In the PSA, the results were robust 
over a range of plausible estimates of model parameters. 
PSA results are presented as means of 1000 probabilistic 
model outputs and were found to be similar to the deter-
ministic results. Based on probabilistic model runs, net 
monetary benefit framework was applied to draw the 
‘incremental cost-effectiveness’ plane (figure 2) which 
shows that TARGIT-IORT is cost saving in 97.8% itera-
tions (figure 3). The CE acceptability chart shows that 
TARGIT-IORT is cost-effective at zero thresholds of WTP.
dIscussIOn
We used published data from the TARGIT-A trial to inves-
tigate the CE of TARGIT-IORT in patients with early breast 
cancer. The findings suggest that in comparison to the 
EBRT which involves delivering whole-breast radiations 
in multiple sessions, individuals treated with TARGIT-
IORT, during the surgery performed to remove the breast 
cancer, had higher mean health gain (QALYs) at a lower 
mean cost. The model outputs indicate definite cost 
savings by the use of TARGIT-IORT within a risk-adapted 
strategy rather than using EBRT in call cases. The model 
runs for 10 years which is very conservative as most events 
related to breast cancer occur in the first 5 years.21 These 
findings, based on extrapolation of the relevant outcomes 
obtained from the analysis of complete trial data, were 
generally found to be robust to uncertainty surrounding 
various model parameter inputs and assumptions. Based 
on probabilistic analysis, TARGIT-IORT had a 98% 
chance of being cost-effective at zero WTP. The one-way 
sensitivity analysis demonstrates that our estimates of the 
ICERs were reasonably robust to a 25% change in the 
base case input values.
The finding that TARGIT-IORT has the highest chance 
of being the most cost-effective option is driven by a 
number of factors: (1) its greater estimated QALY and 
utility gains due to fewer non-breast-cancer deaths in the 
TARGIT-IORT cohort; (2) its lower cost compared with 
EBRT; (3) its non-inferiority to EBRT in terms of cancer 
recurrence; and (4) the high likelihood of its being supe-
rior to EBRT in terms of non-breast-cancer mortality. The 
latter is supported by a recently published meta-analysis 
of partial breast irradiation versus whole-breast irradia-
tion10 and a published correspondence9 which include 
the data from the earliest cohort in the TARGIT-A trial, 
which have a median follow-up of 5 years.
This study provides evidence that TARGIT-IORT is 
an economically attractive intervention in the carefully 
selected eligible patients of early breast cancer. Our 
research has been conducted using recognised economic 
modelling techniques and followed comprehensive Inter-
national Society for Pharmacoeconomics and Outcomes 
Research - Society for Medical Decision Making (ISPOR-
SMDM) task force guidelines on modelling good research 
practices.22 We undertook a wide range of sensitivity anal-
yses and confirmed the robustness of our findings.
In our model, costs associated with management of 
acute and long-term radiotoxicity were not included 
because of similar overall toxicity rates in the two treat-
ments (seroma needing aspiration was more common 
with TARGIT-IORT 2.1% vs 0.8%, while grade 3 or grade 
4 radiation toxicity was more common with EBRT 0.5% 
vs 2%). The low level of radiotoxicity (<3%) is unlikely to 
make a significant cost difference.
The environmental and social costs5 as well as travel 
costs have not been included into the model. These 
are usually borne by the patient, but in many health 
systems they are borne by the health system. In any case, 
these costs including management of toxicity costs will 
further add to the CE of TARGIT-IORT.
We would like to believe that the results of this CE anal-
ysis may be generalisable in many statutory healthcare 
systems. Our belief regarding the generalisability of results 
to other similar healthcare systems is based on the fact 
that EBRT has relatively high costs than TARGIT-IORT 
across the healthcare jurisdictions. TARGIT-IORT costs 
will remain lower than EBRT in most healthcare settings 
because of many factors even if tariffs are different; EBRT 
has a high and recurring investment for the linear accel-
erators and bunkers, associated with need of maintenance 
and personnel attendance; it is labour intensive, which 
is deemed to translate into high personnel costs. More-
over, EBRT is delivered in multiple fractions and patient 
transportation and accommodation costs can be addi-
tionally taken into account. Higher EBRT tariffs from 
other healthcare settings and inclusion of cost of EBRT 
bunker in this analysis will make ICER more favourable to 
TARGIT-IORT.
Complex medical practice is difficult to transform into a 
decision model. This study shares the general limitations of 
economic modelling along with several other limitations. 
Due to data limitations, this analysis used a cohort-based 
model ignoring heterogeneity. The time horizon of the 
CE analysis was not lifetime but 10 years. Extrapolation 
beyond 10 years was not undertaken because of the rela-
tively shorter follow-up period of effectiveness trial. The 
analysis was done from payer’s perspective. A societal 
perspective could measure costs, including impacts on the 
rest of society, patients and families. One weakness of the 
study is that the clinical effectiveness data used to inform 
disease progression in the model are drawn from a single 
albeit large randomised study . Another important limita-
tion was regarding the health state utility weights used in 
the economic model. Although these utilities were taken 
from UK studies using the EQ-5D and valued using the UK 
general population tariff, a small sample size challenges the 
validity of these utility weights.
Our CE model results are in line with the previously 
published studies from Esserman et al,23 Alvarado et al,24 
Picot et al,25 Shah et al26 and Vaidya et al,27 which came to 
the same conclusion that TARGIT-IORT is more cost-ef-
fective than standard EBRT. Newer EBRT techniques such 
as Intensity Modulated Radiotherapy (IMRT) with higher 
equipment and human resource costs the difference 
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between TARGIT-IORT tariffs and EBRT tariffs, even if used 
for partial breast irradiation, would have been even higher.
In our CE model, TARGIT-IORT dominates EBRT. Flip-
ping it on its head, if TARGIT-IORT were the standard 
strategy, there would be no health-economic justification 
for adopting whole breast-EBRT. If no radiation at all is 
implemented for very low-risk patients then no radiation 
dominates TARGIT-IORT, at the cost of higher local recur-
rence rate that may not be acceptable to clinicians and 
patients. The recurrence rate with no radiotherapy even in 
the best prognosis and older patients is up to 1 in 17. With 
TARGIT-IORT with just one selection criterion (oestrogen 
receptor positive) this is very low (1 in 71).
Preferences elicited from health professionals working 
with patients with breast cancer accepted TARGIT-IORT 
as an alternative treatment option to EBRT for early breast 
cancer.28 In this era where decisions are shared by doctors 
and patients, informed by the best evidence available, 
reflect patients’ own values and preferences and involve 
them more directly, TARGIT-IORT has been shown to be 
the preferred choice compared with EBRT by the patients 
as well as the doctors.29-32
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